ClinicalTrials.gg
CompletedNCT06939296Updated Sep 16, 2026

A Research Study of VCT220 in Adult Chinese Participants With Obesity

A Phase 3 interventional study of VCT220 and Placebo in Obesity and Overweight, sponsored by Vincentage Pharma Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Vincentage Pharma Co., Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2024, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
840
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Enrollment
40th of 502
840 · median 120
Started
2024
with 76 others
Phase 3
100 of 600
50 open now
Registered
343rd of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 40th largest by enrollment of the 502 interventional ones that give a count, is one of 77 that started in 2024, is one of 100 in phase 3, and was the 343rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to assess how VCT220 tablets affect the bodyweight in obese or overweight adult participants. Participant will be randomly assigned to the high-dose group, low-dose group, or placebo group. Each participant will take the study drug orally once daily for 12 months.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years, both male and female;
  • At screening, ≥ 28 kg/m² or 24 kg/m² ≤ BMI \< 28 kg/m² with at least one of the following conditions:

    1. Comorbid prediabetes (impaired fasting glucose and/or abnormal glucose tolerance), hypertension, dyslipidemia, or fatty liver (within the past 6 months prior to screening);
    2. Comorbid weight-bearing joint pain (as determined by the investigator, excluding joint pain caused by other diseases);
    3. Obesity-related shortness of breath or obstructive sleep apnea syndrome;
  • Weight change during the past 3 months due to diet and exercise control should not exceed 5% (self-reported); weight change calculation formula: (highest weight - lowest weight in the past 3 months) / highest weight * 100%;
  • Willing and able to maintain a stable diet and exercise regimen throughout the study;
  • Fully understands the purpose of the study, able to communicate well with the investigator, can comprehend and comply with the requirements of this study, and is willing to sign the form

Exclusion criteria

Exclusion Criteria:

  • Patients with type 1, type 2, or other types of diabetes.
  • A history of endocrine diseases or obesity caused by single gene mutations, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing's syndrome, insulinoma, acromegaly, and hypogonadism.
  • A history of weight-loss surgery (except for liposuction performed more than 1 year ago) or plans to undergo weight-loss surgery, use weight-loss devices, or medical equipment during the study.
  • Has used any of the following medications or treatments:

    1. Has previously used any GLP-1 receptor agonists (GLP-1RAs), GLP-1-related multi-target agonists (such as GLP-1/glucose-dependent insulinotropic peptide [GIP] dual receptor agonists, GLP-1 receptor/glucagon receptor [GCGR] dual agonists, GLP-1/GIP/glucagon [GCG] triple receptor agonists, etc.), or combination formulations containing GLP-1RAs (such as exenatide, liraglutide, semaglutide, benaglutide, etc.);
    2. Within the past 6 months prior to screening, has used any approved or unapproved weight-loss medications other than GLP-1 receptor agonists (GLP-1RAs) and GLP-1-related multi-target agonists (such as orlistat, phentermine/topiramate, naltrexone/bupropion, etc.), or weight-affecting herbal medicines, supplements, meal replacements, etc.;
    3. Within the past 3 months prior to screening, has used any antidiabetic medications, such as metformin, α-glucosidase inhibitors, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, thiazolidinediones (TZDs), etc.;
    4. Within the past 3 months prior to screening, has used any medications that may cause significant weight gain, including systemic treatment for more than 1 week, tricyclic antidepressants, antipsychotic or anticonvulsant medications (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, clozapine, olanzapine, valproic acid and its derivatives, lithium salts, methyldopa, etc.).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
840 participants (actual)

Study arms

  • Experimental
    High dose group

    Participants will receive VCT220 orally, once daily, titrate during 8 weeks and maintain at a high dose.

    Drug: VCT220

  • Experimental
    Moderate dose group

    Participants will receive VCT220 orally, once daily, titrate during 6 weeks and maintain at a moderate dose.

    Drug: VCT220

  • Placebo comparator
    Placebo group

    Participants will receive placebo tablets orally, once daily

    Drug: Placebo

Interventions

  • DrugVCT220

    A small molecule GLP-1R drug, film coated tablet

    Also known as: CX11

  • DrugPlacebo

    Placebo tablets

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline in body weight

    Time frame: From baseline to week 34

  2. The proportion of subjects with a body weight reduction ≥5% from baseline

    Time frame: From baseline to week 34

Secondary outcomes

  1. Percentage change from baseline in waist circumference

    Time frame: From baseline to week 34

  2. Percentage change from baseline in body weight

    Time frame: From baseline to week 52

  3. The proportion of subjects with a body weight reduction of ≥10%, ≥15%, and ≥20%

    Time frame: From baseline to week 34 and week 52

  4. The proportion of subjects with a body weight reduction of ≥5% from baseline

    Time frame: From baseline to week 52

  5. Percentage change from baseline in body mass index (BMI)

    Time frame: From baseline to week 52

  6. Percentage change from baseline in waist circumference

    Time frame: From baseline to week 52

  7. Percentage change from baseline in blood pressure

    DBP and SBP

    Time frame: From baseline to week 52

  8. Percentage change from baseline in blood lipid profiles

    TC, TG, LDL-C, and HDL-C

    Time frame: From baseline to week 52

  9. Percentage change from baseline in fasting plasma glucose

    Time frame: From baseline to week 52

  10. Percentage change from baseline in fasting insulin

    Time frame: From baseline to week 52

  11. Percentage change from baseline in Glycosylated Hemoglobin (HbA1c)

    Time frame: From baseline to week 52

  12. Improvement in quality of life

    Measured by Impact of Weight on Quality of Life-Lite Clinical Trials questionnaire(IWQoL-Lite-CT ). The IWQoL-Lite-CT has 20 items, each scored on a 5-point Likert scale, with a total score of 100. Higher scores indicate less negative impact of weight on quality of life.

    Time frame: From baseline to week 52

  13. Improvement in quality of life

    Measured by Medical Outcomes Study 36-Item Short-Form Health Survey questionnaire version 2 (SF-36 v2) . It contains 36 items grouped into 8 domains, Each item is scored based on a predefined scale. Higher scores indicate better health-related quality of life.

    Time frame: From baseline to week 52

Other outcomes

  1. Adverse events, including treatment-emergent adverse events (TEAEs), serious adverse events (SAEs)

    Time frame: From week 0 to week 56

  2. Change from baseline in liver fat content measured by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)

    Time frame: From baseline to week 52

07

Study locations

1 site
  • Peking University People's Hospital ( There are multiple sites in this clinical trial)
    Beijing, Beijing Municipality, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Nov 2025, 11 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 11 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 22, 2025
StartActual
Dec 24, 2024
Primary completionActual
Nov 25, 2025
CompletionActual
Mar 31, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06939296
Lead sponsor
Vincentage Pharma Co., Ltd
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
Dec 24, 2024
Primary completion
Nov 25, 2025
Completion
Mar 31, 2026
Last update
Sep 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VCT220

Start the discussion